» Articles » PMID: 33322667

Is Interleukin 17 (IL-17) Expression A Common Point in the Pathogenesis of Depression and Obesity?

Overview
Journal J Clin Med
Specialty General Medicine
Date 2020 Dec 16
PMID 33322667
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

(1) Background: Activated immune-inflammatory pathways play an important role in the pathogenesis of depression and pathological obesity. Obesity might promote production of cytokine interleukin 17, which plays a significant role in neuro-immune reactions. The study aimed at assessing the relationship between Body Mass Index (BMI) and IL-17 expression, taking into account the clinical psychiatric variables in patients with depression. (2) Methods: A total of 125 participants took part in the study (95 depressed patients, 30 healthy controls). Data concerning the course of depressive disorders and BMI were collected. The severity of depressive symptoms was assessed using the Hamilton Depression Rating Scale (HDRS). Reverse transcription polymerase chain reaction (RT-PCR) was used to assess IL-17 gene expression at the mRNA levels, while enzyme-linked immunosorbent assay (ELISA) was used to assess IL-17 expression at the protein level. (3) Results: Patients with more hospitalizations showed significantly higher IL-17 mRNA expression levels and higher BMI. However, no correlation between BMI and IL-17 expression was found in depressed patients. (4) Conclusions: Our study revealed that BMI does not affect IL-17 expression in patients with depression. However, further studies should be conducted to evaluate the effects of IL-17 inhibition on adipose tissue and vice versa.

Citing Articles

Activation of the interleukin-23/Th17 axis in major depression: a systematic review and meta-analysis.

Moulton C, Malys M, Hopkins C, Rokakis A, Young A, Powell N Eur Arch Psychiatry Clin Neurosci. 2024; .

PMID: 39012496 DOI: 10.1007/s00406-024-01864-2.


Altered serum interleukin-17A and interleukin-23A levels may be associated with the pathophysiology and development of generalized anxiety disorder.

Mamun-Or-Rashid , Roknuzzaman A, Sarker R, Nayem J, Bhuiyan M, Islam M Sci Rep. 2024; 14(1):15097.

PMID: 38956309 PMC: 11219773. DOI: 10.1038/s41598-024-66131-9.


Exploring the Heart-Mind Connection: Unraveling the Shared Pathways between Depression and Cardiovascular Diseases.

Sobolewska-Nowak J, Wachowska K, Nowak A, Orzechowska A, Szulc A, Plaza O Biomedicines. 2023; 11(7).

PMID: 37509542 PMC: 10377477. DOI: 10.3390/biomedicines11071903.


Screening of potential biomarkers in peripheral blood of patients with depression based on weighted gene co-expression network analysis and machine learning algorithms.

Wang Z, Meng Z, Chen C Front Psychiatry. 2022; 13:1009911.

PMID: 36325528 PMC: 9621316. DOI: 10.3389/fpsyt.2022.1009911.


Th17-cells in depression: Implication in multiple sclerosis.

Melnikov M, Lopatina A Front Immunol. 2022; 13:1010304.

PMID: 36189272 PMC: 9515534. DOI: 10.3389/fimmu.2022.1010304.


References
1.
Luppino F, de Wit L, Bouvy P, Stijnen T, Cuijpers P, Penninx B . Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010; 67(3):220-9. DOI: 10.1001/archgenpsychiatry.2010.2. View

2.
Ogyu K, Kubo K, Noda Y, Iwata Y, Tsugawa S, Omura Y . Kynurenine pathway in depression: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2018; 90:16-25. DOI: 10.1016/j.neubiorev.2018.03.023. View

3.
Garg R, Saxena S, Bashir S . Is obesity a risk to depression? A cross-sectional study. Ind Psychiatry J. 2019; 28(1):130-134. PMC: 6929221. DOI: 10.4103/ipj.ipj_59_19. View

4.
Chen Y, Jiang T, Chen P, Ouyang J, Xu G, Zeng Z . Emerging tendency towards autoimmune process in major depressive patients: a novel insight from Th17 cells. Psychiatry Res. 2010; 188(2):224-30. DOI: 10.1016/j.psychres.2010.10.029. View

5.
Deodhar A, Mease P, McInnes I, Baraliakos X, Reich K, Blauvelt A . Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019; 21(1):111. PMC: 6498580. DOI: 10.1186/s13075-019-1882-2. View